Vor Biopharma INC 10-K annual reports
Annual reports — audited financials, the full risk-factor list, and management’s account of the year.
NASDAQ
Vor Biopharma refocused on autoimmune drug telitacicept, advanced two global Phase 3 trials, reported a $696.0M 2025 net loss driven by a $222.6M license charge and warrant revaluation, and announced a $75.0M private placement to extend cash runway into early 2029.
NASDAQ
Vor Biopharma's 2024 10-K filing details the company's ongoing clinical trials, preclinical programs, and financial position, emphasizing its cell and genome engineering approach to treating AML.
NASDAQ
Vor Biopharma, a clinical-stage company, provided an update on its financial results for 2023 and progress in its clinical programs, including trem-cel and VCAR33 ALLO.